Bruce Spohler
Analyst · JMP Securities
Thank you, Rich. Overall, the financial health of our portfolio companies remained sound, reflecting our disciplined underwriting and focus on downside protection. At June 30, the weighted average investment risk rating of Solar's portfolio was just under 2x when measured at fair market value, based on our 1 to 4 risk rating scale, with 1 representing the least amount of risk. As further indication of the strong underlying fundamentals of our portfolio, only 1% of our portfolio at fair value was on watch list status. This is near historic close. Additionally, 100% of our portfolio was performing at quarter end. At June 30, over 78% of Solar's income-producing portfolio was floating rate when measured at fair value. The fixed rate loan exposure principally comes from NEF's short-duration equipment financings with an average life of just over two years. At quarter end, our comprehensive portfolio encompassed 230 distinct issuers across 97 industries. The average investment per issuer was just over $7.5 million or 0.4% of the overall portfolio. Also at June 30, over 98% of our portfolio consisted of senior secured loans comprised of approximately 83% first lean senior secured loans and just under 15% in second lien secured loans. While our exposure to higher-risk and higher-yielding second lien loans is down from approximately 20% in the first quarter, the weighted average yield of our portfolio was 10.9% compared to 10.8% in Q1. We have been able to maintain this yield of close to 11% at the asset level in spite of spread compression in the cash flow lending market and have replaced our second lien exposure with lower-risk, high-return commercial finance investments. Including activity across our 4 business lines, originations totaled approximately $260 million and repayments were approximately $295 million, resulting in net portfolio reduction of approximately $35 million. Given the continued heated cash flow market conditions, we intentionally allowed that portfolio to shrink. The modest decline in our cash flow portfolio was predominantly from the repayment of second lien assets and, again, was partially offset by growth through our ABL strategies, which, today, offer more favorable risk return characteristics. Now let me give a brief update on each of our 4 investment verticals. Our cash flow business invests in senior secured loans, which are predominately first lien and stretched first lien, to sponsor-backed companies in the upper mid-market with average EBITDA of approximately $70 million today. Included in this vertical are senior secured cash flow loans held both on balance sheet as well as in our SSLPs. During the second quarter, we originated cash flow investments of approximately $45 million and had repayments of approximately $122 million. At June 30, our cash flow loan portfolio was just over $600 million, representing 34% of our $1.8 billion total portfolio. Our exposure to second lien loans declined again to 15% of this portfolio, down from 20% in Q1. We expect this to continue to decline during the remainder of 2018. At June 30, the weighted average trailing 12-month revenue and EBITDA for our issuers were up mid-single-digits, reflecting continued positive fundamental trends for our portfolio companies. In the cash flow segment, leverage to our security was just under 5x, slightly lower than first quarter, and interest coverage was approximately 2.3x. In addition, the weighted average yield on our cash flow investments was 9.6%, consistent with the prior quarter. Turning to our asset-based lending business, Crystal Finance. These loans, as you may recall, are made up of loans against realizable liquidation value of -- and underlying borrowers' assets, and they come with meaningful upfront and prepayment fees as well as structural protections. During the second quarter, we funded $108 million of new asset-based investments and had repayments of approximately $67 million, resulting in portfolio growth of just over $40 million. At June 30, the senior secured asset-based portfolio was approximately $567 million, representing 32% of our total portfolio. The weighted average yield of the asset-based portfolio was 12.3%, up slightly from the first quarter of 12.1%. Our ABL platform paid Solar Capital a second quarter dividend of $7.5 million, equating to a 10.7% yield on cost. Moving on to our equipment finance business, NEF. Solar Capital entered this business through the acquisition of NEF last year. Included in this business are equipment financings held both directly on Solar's balance sheet as well as in our wholly owned subsidiary, NEF Holdings, that for tax efficiency, holds certain of these investments. During the second quarter, NEF had new investments of approximately $60 million and had portfolio repayments of approximately $25 million. At quarter and, our equipment finance strategy had a total portfolio of approximately $350 million of funded assets to 136 different borrowers with an average exposure $2.6 million. The equipment finance asset class represents approximately 20% of our total portfolio. 100% of NEF's investments are first lien loans and approximately 95% are fixed rate. The interest rate risk is mitigated through the relatively short holding period of just over two years as well as our efforts to match fund NEF's assets with our unsecured fixed rate liabilities of approximately $250 million. The weighted average yield on our equipment finance portfolio was 10.5% at quarter end, consistent with the prior quarter. Finally, a brief update on our life science lending business. As a reminder, these are first lien senior secured loans and typically come with either success fees or warrants to enhance our yield. During the second quarter, our team originated just under $50 million of new senior secured life science loans. Repayments totaled approximately $80 million. Our life science portfolio totaled approximately $204 million at quarter end across 19 borrowers with an average investment size of just over $10 million. Our life science loans represent just over 11% of our total portfolio. The weighted average yield on the life science portfolio is approximately 12% and, again, excluding any exit, success fees and warrants. As Michael mentioned, the middle-market cash flow lending environment remains frothy. We have solid benefit from our diversified origination sources across not only cash flow but also asset-based lending vertical, which allow us to allocate capital to investments that meet our strict underwriting criteria regardless of market conditions. We will continue to be prudent and highly disciplined in deploying our substantial available capital. Now I'll turn the call back to Michael.